Anne Keating

TL;DR: YM155 has modest activity in taxane-pretreated CRPC with 25% of patients having prolonged stable disease (≥18 weeks) and the regimen appears to be well tolerated.

TL;DR: The combination of S (10 mg/m(2)/day 72-h CIVI) administered with C and P every 3 weeks exhibited a favorable safety profile but failed to demonstrate an improvement in response rate in advanced NSCLC.

TL;DR: This phase II study was conducted to better characterize the toxicity and efficacy of this small molecule in patients with refractory DLBCL.

TL;DR: Although YM 155 is a novel drug that suppresses survivin, YM155 plus docetaxel exhibited no statistically significant differences in endpoints compared with docetAXel alone, and the combination regimen was well tolerated.

TL;DR: YM155 was generally well tolerated, but the predetermined primary efficacy endpoint (i.e., 6‐month PFS rate ≥20%) was not achieved, and YM155 is a novel agent showing modest activity when combined with docetaxel for treating patients with melanoma.